MaaT Pharma Receives Positive Opinion from DSMB for MaaT013 in P-III Trial to Treat Graft Versus Host Disease (GvHD)
Shots:
- The Independent DSMB has recommended the continuation of P-III (ARES) development for MaaT013, targeting acute GvHD patients (n=75, Grade II-IV), refractory to steroids and resistant to ruxolitinib
- This positive outcome is based on interim data from 30 patients on Day 28, demonstrating improved efficacy and no safety concerns. The study maintains a positive benefit-risk ratio and boasts a superior Overall Response Rate
- MaaT013, a donor-derived microbiome ecosystem therapy (MET technology) features Butycore, a bacterial species producing anti-inflammatory short-chain fatty acids and has obtained ODD from both the US FDA and EMA
Ref: MaaT Pharma | Image: MaaT Pharma
Related News:- The US FDA Lifts Clinical Hold for MaaT Pharma’s MaaT013 to Treat Acute Graft-versus-Host Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
